MedTrace Logo

Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency

NCT02547532 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-08-01

No results posted yet for this study

Summary

In the context of the increasing evidence of the pathogenetic role of microbiome in COPD, our aim is to determine the total and specific bacterial and viral load in sputa from patients with COPD due to AATD and to correlate these findings with cellular, biochemical and immunological characteristics of sputa. These quantitative data obtained from sputum will be analyzed in the context of the clinical and physiological parameters of the patients.

Conditions

  • Alpha-1 Antitrypsin Deficiency

Interventions

OTHER

collection of sputum

Sponsors & Collaborators

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    collaborator OTHER

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

    collaborator OTHER

  • Grifols Biologicals, LLC

    collaborator INDUSTRY

  • Fondazione Salvatore Maugeri

    lead OTHER

Principal Investigators

  • Pantaleo Giannuzzi, M.D. · Fondazione Salvatore Maugeri

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-04-30
Completion
2018-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02547532 on ClinicalTrials.gov